Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

NCT04930536 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma

Interventions

DRUG: Acalabrutinib capsule

Sponsor

AstraZeneca